Cite
HARVARD Citation
Mo, M. et al. (2022). The safety and efficacy evaluation of sodium-glucose co-transporter 2 inhibitors for patients with non-alcoholic fatty liver disease: An updated meta-analysis. Digestive and liver disease. 54 (4), pp. 461-468. [Online].